Abstract
Urothelial tumors develop along two distinctive phenotypic pathways (superficial papillary non-invasive tumors versus flat carcinoma in situ lesions), with markedly different biological behavior and prognosis. Although multiple genetic alterations have been identified in human bladder cancer, their cause–effect relationship with the two pathways has not been firmly established. Using a urothelium-specific promoter of the uroplakin II gene, we showed earlier in transgenic mice that the urothelial expression of SV40T antigen, which inactivates p53 and pRb, induced carcinoma in situ and invasive and metastatic bladder cancer. In striking contrast, we demonstrate here that the urothelial expression of an activated Ha-ras in transgenic mice caused urothelial hyperplasia and superficial papillary non-invasive bladder tumors. These results provide strong, direct experimental evidence that the two phenotypical pathways of bladder tumorigenesis are caused by distinctive genetic defects. Our results indicate that Ha-ras activation can induce urothelial proliferation in vivo; and that urothelial hyperplasia is a precursor of low-grade, superficial papillary bladder tumors. Our transgenic models provide unique opportunities to study the detailed molecular events underlying different types of bladder neoplasms, and can serve as useful preclinical models for evaluating the in vivo efficacy of preventive and therapeutic agents that act on various signaling pathways in bladder cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amundadottir LT, Leder P . 1998 Oncogene 16: 737–746
Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM . 1997 Genes Chromosomes Cancer 19: 84–89
Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B . 1999 Oncogene 18: 1197–1203
Bos JL . 1989 Cancer Res. 49: 4682–4689
Brinster RL, Chen HY, Trumbauer M, Senear AW, Warren R, Palmiter RD . 1981 Cell 27: 223–231
Brinster RL, Palmiter RD . 1986 The Harvey Lectures 80: 1–38
Bryan TM, Reddel RR . 1994 Crit. Rev. Oncog. 5: 331–357
Burchill SA, Lunec J, Mellon K, Neal DE . 1991 Br. J. Cancer 63: Suppl. XIII 62 abstract
Burchill SA, Neal DE, Lunec J . 1994 Br. J. Urol. 73: 516–521
Cahill MA, Janknecht R, Nordheim A . 1996 Curr. Biol. 6: 16–19
Campbell SC, Volpert OV, Ivanovich M, Bouck NP . 1998 Cancer Res. 58: 1298–1304
Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV . 1983 Nature 302: 33–37
Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hara R, Pantginis J, Zhou H, Horner JW, Cordon-Cardo C, Yancopoulos GD, DePinho RA . 1999 Nature 400: 468–472
Cordon-Cardo C, Dalbagni G, Sarkis AS, Reuter VE . 1994 Important Adv. Oncol 71–83
Corominas M, Sloan SR, Leon J, Kamino H, Newcomb EW, Pellicer A . 1991 Environ. Health Perspect. 93: 19–25
Czerniak B, Cohen GL, Etkind P, Deitch D, Simmons H, Herz F, Koss LG . 1992 Hum. Pathol. 23: 1199–1204
Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C . 1993 Lancet 342: 469–471
Dunn TL, Seymour GJ, Gardiner RA, Strutton GM, Lavin MF . 1988 J. Pathol. 156: 59–65
Enomoto T, Ward JM, Perantoni AO . 1990 Carcinogenesis 11: 2233–2238
Fasano O, Aldrich T, Tamanoi F, Taparowsky E, Furth M, Wigler M . 1984 Proc. Natl. Acad. Sci. USA 81: 4008–4012
Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, Summerhayes IC . 1995 J. Natl. Cancer Inst. 87: 129–133
Gibbs JB, Oliff A, Kohl NE . 1994 Cell 77: 175–178
Grossman HB . 1996 Oncology (Huntingt) 10: 1617–1624 discussion 1624, 1627, 1628
Knowles MA, Williamson M . 1993 Cancer Res. 53: 133–139
Koss LG . 1992 J. Cell. Biochem. 16I: 23–29
Kunze E, Chowaniec J . 1990 In Turosov V and Mohr U (eds.), Tumors of the Urinary Bladder International Agency for Research on Cancer, Lyon 1: pp. 345–373
Leder A, Kuo A, Cardiff RD, Sinn E, Leder P . 1990 Proc. Natl. Acad. Sci. USA 87: 9178–9182
Levesque P, Ramchurren N, Saini K, Joyce A, Libertino J, Summerhayes IC . 1993 Int. J. Cancer 55: 785–790
Lin JH, Zhao H, Sun TT . 1995 Proc. Natl. Acad. Sci. USA 92: 679–683
Masui T, Mann AM, Borgeson CD, Garland EM, Okamura T, Fujii H, Pelling JC, Cohen SM . 1993 Teratog. Carcinog. Mutagen. 13: 225–233
Messing EM . 1992 Semin. Surg. Oncol. 8: 285–292
Ogawa K, Uzvolgyi E, St John MK, de Oliveira ML, Arnold L, Cohen SM . 1998 Mol. Carcinog. 21: 70–79
Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, Fukushima S, Niijima T . 1986 Cancer Res. 46: 2001–2004
Olson MF, Marais R . 2000 Semin. Immunol. 12: 63–73
Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C . 1995 J. Natl. Cancer Inst. 87: 1524–1529
Orntoft TF, Wolf H . 1998 Urol. Res. 26: 223–233
Oyasu R . 1995 Food Chem. Toxicol. 33: 747–755
Quaife CJ, Pinkert CA, Ornitz DM, Palmiter RD, Brinster RL . 1987 Cell 48: 1023–1034
Rassoulzadegan M, Cuzin F . 1987 Oncogene Res. 1: 1–6
Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, Cuthill S . 1996 Semin. Oncol. 23: 571–584
Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D . 1995 Cancer Res. 55: 5213–5216
Saito S . 1992 Keio J. Med. 41: 80–86
Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL . 1989 Oncogene 4: 715–724
Schalken JA, van Moorselaar RJ, Bringuier PP, Debruyne FM . 1992 Semin. Surg. Oncol. 8: 274–278
Schneider BL, Bowden GT . 1992 Mol. Carcinog. 6: 1–4
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . 1997 Cell 88: 593–602
Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, Jones PA . 1994 Cancer Res. 54: 784–788
Steinberg GD, Trump DL, Cummings KB . 1992 Urol. Clin. North Am. 19: 735–746
Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS . 1990 Proc. Natl. Acad. Sci. USA 87: 9047–9051
Vageli D, Kiaris H, Delakas D, Anezinis P, Cranidis A, Spandidos DA . 1996 Cancer Lett. 107: 241–247
Visvanathan KV, Pocock RD, Summerhayes IC . 1988 Oncogene Res. 3: 77–86
Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, Waldman FM . 1995 Hum. Pathol. 26: 970–978
Walker RE . 1960 Am. J. Anat. 102: 95–100
Yamamoto S, Masui T, Murai T, Mori S, Oohara T, Makino S, Fukushima S, Tatematsu M . 1995 Carcinogenesis 16: 2363–2368
Ye DW, Zheng JF, Qian SX, Ma YJ . 1993 Urol. Res. 21: 39–43
Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR . 1999 Cancer Res. 59: 3512–3517
Acknowledgements
We wish to thank Dr Herbert Lepor for his continued support and encouragement for this work. The current study was supported in part by a Merit Review grant from Veterans Administration Research Service to X-R Wu, and by NIH grants to X-R Wu (DK52206 and DK56903), A Pellicer (DK52206) and T-T Sun (DK52206, DK39753, DK57269).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhang, ZT., Pak, J., Huang, HY. et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20, 1973–1980 (2001). https://doi.org/10.1038/sj.onc.1204315
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204315
Keywords
This article is cited by
-
Immunohistochemical expressions of EMT markers in pan-RAS–pERK1/2-positive tumors improve diagnosis and prognosis assessment of non-muscle invasive bladder cancer and muscle invasive bladder cancer patients
Molecular and Cellular Biochemistry (2023)
-
Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis
Nature Communications (2021)
-
The duality of human oncoproteins: drivers of cancer and congenital disorders
Nature Reviews Cancer (2020)
-
Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS
Scientific Reports (2019)
-
SIU–ICUD consultation on bladder cancer: basic science
World Journal of Urology (2019)